VIRACTA THERAP.I.DL-0001
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trial… Read more
VIRACTA THERAP.I.DL-0001 (RYI) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, VIRACTA THERAP.I.DL-0001 (RYI) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
VIRACTA THERAP.I.DL-0001 - Net Assets Trend (None–None)
This chart illustrates how VIRACTA THERAP.I.DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for VIRACTA THERAP.I.DL-0001 (None–None)
The table below shows the annual net assets of VIRACTA THERAP.I.DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to VIRACTA THERAP.I.DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
VIRACTA THERAP.I.DL-0001 Competitors by Market Cap
The table below lists competitors of VIRACTA THERAP.I.DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beasley Broadcast Group Inc
NASDAQ:BBGI
|
$2.28 Million |
|
4LE
F:4LE
|
$2.28 Million |
|
ECM Libra Financial Group Bhd
KLSE:2143
|
$2.28 Million |
|
MBANK (BRU.SG)
STU:BRU
|
$2.28 Million |
|
Fobi AI Inc
OTCQB:FOBIF
|
$2.28 Million |
|
Daishin Balance 1
KQ:217270
|
$2.28 Million |
|
Semacom Integrated Tbk PT
JK:SEMA
|
$2.28 Million |
|
Tourn International AB
ST:TOURN
|
$2.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VIRACTA THERAP.I.DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares VIRACTA THERAP.I.DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently VIRACTA THERAP.I.DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares VIRACTA THERAP.I.DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VIRACTA THERAP.I.DL-0001 (RYI) | €- | N/A | N/A | $2.28 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |